IRIS

Daver, N.g., Wei, A.h., Stein, E.m., Deangelo, D.j., Pathak, D., Xu, Y., et al. (2022). AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 22, 217-217 [10.1016/S2152-2650(22)01228-9].

AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC)

Venditti A.
2022-01-01
2022
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Con Impact Factor ISI
acute myeloid leukemia
clinical trial
azacitidine
p53
venetoclax
trial in progress
Daver, N.g., Wei, A.h., Stein, E.m., Deangelo, D.j., Pathak, D., Xu, Y., et al. (2022). AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 22, 217-217 [10.1016/S2152-2650(22)01228-9].
Daver, Ng; Wei, Ah; Stein, Em; Deangelo, Dj; Pathak, D; Xu, Y; Grzesiak, S; Venditti, A
Articolo su rivista
01 - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/306895
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact